Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Biogen (BIIB)

Biogen Q2 revenue rises 3% to $2.7 billion; full-year EPS guidance cut to $12-$13

Mixed Impact 4 of 5 guidance Written later

Biogen reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, but diluted EPS fell sharply as deal-related charges and the Apellis acquisition weighed on results. The company cut its full-year 2026 Non-GAAP diluted EPS guidance to $12.00 to $13.00, down from $14.25 to $15.25 in April, which lowers the outlook for shareholders.

Key points

  • Q2 2026 GAAP diluted EPS was $0.66, down from $4.33 a year earlier; Non-GAAP diluted EPS was $3.60, down from $5.47
  • Full-year 2026 Non-GAAP diluted EPS guidance is $12.00 to $13.00, versus $14.25 to $15.25 reported in April
  • Full-year total revenue is now expected to rise by a mid-single-digit percentage in 2026 compared with 2025
  • Q2 2026 acquired IPR&D, upfront and milestone expense was $164 million, versus $47 million a year earlier

The filing

CompanyBiogen (BIIB)
Form8-K, current report
Filed with the SECJul 29, 2026, 6:10 AM ET
Accession number0000875045-26-000073

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.